



1.29.01

TO THE ASSISTANT COMMISSIONER FOR I

101605158

Documents or copy thereof.

1. Name of conveying party(ies): (If multiple assignors, list numerically)


Medical Biology Institute

Additional name(s) of conveying party(ies) attached? ( ) Yes (X) No

2. Name and address of receiving party(ies):

Name: Torrey Pines Institute for Molecular Studies
Internal Address:
Street Address: 3550 General Atomics Court, Bldg. 2, Room 129
City: San Diego State: CA ZIP: 92121

Additional name(s) of receiving party(ies) attached? ( ) Yes (X) No



3. Nature of conveyance:

- ( ) Assignment
( ) Merger
( ) Security Agreement
( ) Change of Name
(X) Other: Quitclaim

Execution Date: (If multiple assignors, list execution dates in numerical order corresponding to numbers indicated in 1 above) 1/28/99 and 1/21/99

4. Application number(s) or Patent number(s):

- ( ) Application(s) filed herewith
Execution Date(s):
( ) Patent Application No.:
Filing Date:
( ) Patent No.:
Issue Date:

Additional numbers attached? ( ) Yes (X) No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Mark R. Benedict
KNOBBE, MARTENS, OLSON & BEAR, LLP
Customer No. 20,995
Internal Address: Sixteenth Floor
Street Address: 620 Newport Center Drive
City: Newport Beach State: CA ZIP: 92660
Attorney's Docket No.: LANCELL.002A

7. Total fee (37 CFR 3.41): \$40

- (X) Enclosed
(X) Authorized to be charged to deposit account if any additional fees are required, or to credit any overpayment

8. Deposit account number: 11-1410

Please charge this account for any additional fees which may be required, or credit any overpayment to this account.

6. Total number of applications and patents involved: N/A

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct, and any attached copy is a true copy of the original document.

Mark R. Benedict
Name of Person Signing

Signature: [Handwritten Signature]

Date: 1/25/01

44,531
Registration No.

Total number of pages including cover sheet, attachments and document: 4

Mail documents to be recorded with required cover sheet information to:

02/05/2001 6TOM11 00000044 MARK R. BENEDICT
01 FC:581 40.00 OP

Assistant Commissioner for Patents
Box Assignments
Washington, D.C. 20231

H:\DOCS\MRB\MRB-2166.DOC:is
012501



## QUITCLAIM OF SELECTED PATENTED TECHNOLOGIES

WHEREAS, Medical Biology Institute is a non-profit public benefit California Corporation, which has in the past been the recipient of federal grant monies;


WHEREAS, Medical Biology Institute is in the possession of certain patented technologies, more particularly described in Exhibits A and B hereto;

WHEREAS, Torrey Pines Institute for Molecular Studies is a non-profit public benefit California Corporation, which is the recipient of federal grant monies;


THE PARTIES HERETO AGREE AS FOLLOWS:

- 1 Pursuant to the policy of Medical Biology Institute and its board of directors to transfer the technologies associated with the work of the scientists, at the time grants are transferred, Medical Biology Institute hereby transfers to Torrey Pines Institute for Molecular Studies those technologies known as ADIFAB and Langerhans, more particularly described in the attached hereto as Exhibits A and B, by quitclaim of all right title or interest it may have in said technologies;
2. This transfer is without warranty as to the rights, title or interest Medical Biology Institute may have in such technology.

Dated: 1/28/99

  
Richard Houghten, President  
Torrey Pines Institute for  
Molecular Studies

Dated: 1/21/99

  
Christopher S. McKellar, CEO  
Medical Biology Institute

**EXHIBIT "A" TO QUITCLAIM OF PATENTED TECHNOLOGY**

The technology transferred pursuant to the Quitclaim of Selected Patented Technologies to which this Exhibit "A" is attached, refers to the technology patented and owned by Medical Biology Institute, and which technology Medical Biology Institute is also the assignee of all right, title, and interest in and to the technology known as ADIFAB, generally defined or referred to as the technology which shall mean fluorescently modified fatty acid binding proteins.

This patented technology, ADIFAB, of which Medical Biology Institute is the owner or assignee of all right, title, and interest in and to the patent applications respecting the ADIFAB technology, is also known as: U.S. Patent No. 5,470,714 - issued 11/28/95 entitled "One-Step Free Fatty Acid Determination Method", also known as European Patent Number 0457901 - issued 11/08/95 entitled "Free Fatty Acid Determination", and also known as PCT App. No. PCT/US97/10400 - filed 06/13/97 entitled "Method of Detection of Cardiac Ischemia Using Fatty Acid Binding Protein."

The technology identified above through description and by reference to the patents and application, is licensed exclusively to FFA Sciences, LLC, a California Limited Liability Company. A copy of the License Agreement is attached hereto and incorporated as part of this Exhibit "A."

**EXHIBIT "B" TO QUITCLAIM OF PATENTED TECHNOLOGY**

**The technology transferred pursuant to the Quitclaim of Selected Patented Technologies to which this Exhibit "B" is attached, refers to the technology patented and owned by Medical Biology Institute, and which technology Medical Biology Institute is also the assignee of all right, title, and interest in and to the technology designed to promote topical delivery of peptide vaccines and to enhance their efficacy by concomitant topical application of an inducer of Langerhans cell migration (hereinafter called the "Langerhans Cell Technology").**

**This patented technology, Langerhans Cell Technology, of which Medical Biology Institute is the owner or assignee of all right, title, and interest in and to the patent applications respecting the Langerhans Cell Technology, is also known as PCT App. No. PCT/US98/07817- filed 04/20/98, and U.S. App. No. 09/176,044 – filed 10/20/98.**

**The technology identified above through description and by reference to the patent applications, is exclusively licensed to LANCELL, L.L.C., a California Limited Liability Company. A copy of the License Agreement is attached hereto and incorporated as part of this Exhibit "B."**